WWA
VRTX icon

Wingate Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Wingate Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-108
Closed -$43.5K – 443
2024
Q4 		$43.5K Buy
+108
New +$50.1K 0.04% 234

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Wingate Wealth Advisors's VRTX Position: Q1 2025 in Review

Wingate Wealth Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q1 2025, closing a stake of 108 shares — an estimated $43.5K sold.

Wingate Wealth Advisors first reported a position in VRTX in Q4 2024 and held it in 1 quarter. The position peaked at $43.5K in Q4 2024. 1,613 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

  • Wingate Wealth Advisors reported no remaining Vertex Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Wingate Wealth Advisors sold 108 Vertex Pharmaceuticals shares in Q1 2025, an estimated $43.5K.
  • Wingate Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Wingate Wealth Advisors's Vertex Pharmaceuticals position peaked at $43.5K in Q4 2024.
  • 1,613 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Wingate Wealth Advisors's 13F filing for Q1 2025, filed 24 Apr 2025.